/TELA
TELA Stock - TELA Bio, Inc.
Healthcare|Medical - DevicesNASDAQ
$1.13-0.88%
$0.01 (-0.88%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+114.2%upside
Target: $2.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TELA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.12 – $1.14
TARGET (TP)$2.42
STOP LOSS$1.04
RISK/REWARD1:14.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.87
52W High$3.10
52W Low$0.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $69.30M | $58.45M | $41.42M | $29.46M | $18.21M |
| Gross Profit | $46.49M | $40.11M | $27.04M | $18.81M | $11.23M |
| Gross Margin | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% |
| Operating Income | $-34,115,000 | $-44,075,000 | $-39,007,000 | $-29,451,000 | $-25,275,000 |
| Net Income | $-37,841,000 | $-46,664,000 | $-44,296,000 | $-33,276,000 | $-28,794,000 |
| Net Margin | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% |
| EPS | $-1.33 | $-2.04 | $-2.73 | $-2.30 | $-2.23 |
Company Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$10
Average Target
↑ 740.7% Upside
Now
$2
Low
$10
Average
$17
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 21st 2025 | Piper Sandler | Downgrade | Neutral | $2← $5 |
| May 31st 2022 | Lake Street | Initiation | Buy | $17 |
Earnings History & Surprises
TELABeat Rate
28%
Last 18 quarters
Avg Surprise
-8.6%
EPS vs Estimate
Beats / Misses
5/13
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
-20.5%
$-0.53vs$-0.44
Q2 24
+52.1%
$-0.23vs$-0.48
Q3 24
-13.3%
$-0.51vs$-0.45
Q4 24
-13.5%
$-0.42vs$-0.37
Q1 25
+4.2%
$-0.23vs$-0.24
Q2 25
-19.0%
$-0.25vs$-0.21
Q3 25
-22.2%
$-0.22vs$-0.18
Q4 25
-11.8%
$-0.19vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.18 | $-0.22 | -22.2% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.37 | $-0.42 | -13.5% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.48 | $-0.23 | +52.1% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.44 | $-0.53 | -20.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.52 | $-0.45 | +13.5% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.58 | $-0.46 | +20.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.51 | $-0.63 | -23.5% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $-0.58 | $-0.52 | +10.3% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.57 | $-0.64 | -12.3% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.60 | $-0.80 | -33.3% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.50 | $-0.75 | -50.0% | ✗ MISS |
Q1 2022 | Mar 21, 2022 | $-0.54 | $-0.59 | -9.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.52 | $-0.57 | -9.6% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.49 | $-0.57 | -16.3% | ✗ MISS |
Latest News
Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $3
➖ NeutralBenzinga•Dec 1, 2025, 05:03 PM
Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $4
➖ NeutralBenzinga•Nov 18, 2025, 11:52 AM•Also:
Piper Sandler Reiterates Neutral on TELA Bio, Lowers Price Target to $1.25
➖ NeutralBenzinga•Nov 14, 2025, 04:18 PM
Citizens Maintains Market Outperform on TELA Bio, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 14, 2025, 03:29 PM
TELA Bio FY2025 Revenue expected to be more than $80.388M vs $85.416M Est
📉 NegativeBenzinga•Nov 13, 2025, 10:10 PM
TELA Bio Prices ~$13M Common Stock, Pre-Funded Offering
➖ NeutralBenzinga•Nov 13, 2025, 09:23 PM
TELA Bio Q3 EPS $(0.19) Beats $(0.20) Estimate, Sales $20.700M Miss $21.788M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:05 PM
Frequently Asked Questions about TELA
What is TELA's current stock price?
TELA Bio, Inc. (TELA) is currently trading at $1.13 per share. The stock has moved -0.88% today.
What is the analyst price target for TELA?
The average analyst price target for TELA is $2.42, based on 1 analyst.
What sector is TELA Bio, Inc. in?
TELA Bio, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is TELA's market cap?
TELA Bio, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does TELA pay dividends?
No, TELA Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CTSO
Cytosorbents Corporation
$0.64
Mkt Cap: $0.0B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
ICCM
IceCure Medical Ltd
$0.67
Mkt Cap: $0.0B
MDAI
Spectral AI, Inc.
$1.55
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
SRTS
Sensus Healthcare, Inc.
$3.83
Mkt Cap: $0.1B
Explore stocks similar to TELA for comparison